{"id":24704,"date":"2023-11-07T09:02:00","date_gmt":"2023-11-07T09:02:00","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=24704"},"modified":"2026-03-20T14:39:21","modified_gmt":"2026-03-20T21:39:21","slug":"perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/vi\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/","title":{"rendered":"Perjeta (Pertuzumab): M\u1ed9t lo\u1ea1i thu\u1ed1c \u0111\u1ea7y h\u1ee9a h\u1eb9n cho b\u1ec7nh ung th\u01b0 v\u00fa d\u01b0\u01a1ng t\u00ednh v\u1edbi HER2"},"content":{"rendered":"<p>HER2 (th\u1ee5 th\u1ec3 y\u1ebfu t\u1ed1 t\u0103ng tr\u01b0\u1edfng bi\u1ec3u b\u00ec ng\u01b0\u1eddi 2) l\u00e0 m\u1ed9t lo\u1ea1i protein \u0111\u01b0\u1ee3c t\u00ecm th\u1ea5y tr\u00ean b\u1ec1 m\u1eb7t c\u1ee7a m\u1ed9t s\u1ed1 t\u1ebf b\u00e0o (v\u00ed d\u1ee5, t\u1ebf b\u00e0o v\u00fa) c\u00f3 vai tr\u00f2 trong qu\u00e1 tr\u00ecnh t\u0103ng tr\u01b0\u1edfng v\u00e0 ph\u00e2n chia t\u1ebf b\u00e0o.&nbsp;<\/p>\n\n\n\n<p>\u0110\u00f4i khi, c\u00e1c t\u1ebf b\u00e0o ung th\u01b0 v\u00fa c\u00f3 th\u1ec3 c\u00f3 qu\u00e1 nhi\u1ec1u b\u1ea3n sao c\u1ee7a gen HER2, d\u1eabn \u0111\u1ebfn qu\u00e1 nhi\u1ec1u protein HER2 tr\u00ean b\u1ec1 m\u1eb7t t\u1ebf b\u00e0o. T\u00ecnh tr\u1ea1ng n\u00e0y \u0111\u01b0\u1ee3c g\u1ecdi l\u00e0 ung th\u01b0 v\u00fa d\u01b0\u01a1ng t\u00ednh v\u1edbi HER2. Gi\u1edbi thi\u1ec7u&nbsp;<a href=\"https:\/\/www.cancer.org\/cancer\/breast-cancer\/understanding-a-breast-cancer-diagnosis\/breast-cancer-her2-status.html\">15% \u0111\u1ebfn 20%<\/a>&nbsp;kh\u1ed1i u v\u00fa c\u00f3 m\u1ee9c \u0111\u1ed9 HER2 cao h\u01a1n.&nbsp;<\/p>\n\n\n\n<p>C\u00e1c l\u1ef1a ch\u1ecdn \u0111i\u1ec1u tr\u1ecb ung th\u01b0 d\u01b0\u01a1ng t\u00ednh v\u1edbi HER2 c\u00f3 th\u1ec3 bao g\u1ed3m ph\u1eabu thu\u1eadt, x\u1ea1 tr\u1ecb, h\u00f3a tr\u1ecb, li\u1ec7u ph\u00e1p hormone v\u00e0 c\u00e1c li\u1ec7u ph\u00e1p nh\u1eafm m\u1ee5c ti\u00eau nh\u01b0 Perjeta (pertuzumab). B\u00e0i vi\u1ebft n\u00e0y n\u00eau b\u1eadt hi\u1ec7u qu\u1ea3 c\u1ee7a Perjeta trong \u0111i\u1ec1u tr\u1ecb ung th\u01b0 d\u01b0\u01a1ng t\u00ednh v\u1edbi HER2 v\u00e0 gi\u1ea3i th\u00edch c\u01a1 ch\u1ebf ho\u1ea1t \u0111\u1ed9ng c\u0169ng nh\u01b0 c\u00e1ch s\u1eed d\u1ee5ng thu\u1ed1c trong \u0111i\u1ec1u tr\u1ecb.<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Chuy\u1ec3n \u0111\u1ed5i m\u1ee5c l\u1ee5c\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Chuy\u1ec3n \u0111\u1ed5i<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/vi\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#What_Is_Perjeta\" >Perjeta l\u00e0 g\u00ec?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/vi\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#What_Is_Perjeta_Used_For\" >Perjeta \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng \u0111\u1ec3 l\u00e0m g\u00ec?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/vi\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#How_Does_Perjeta_Work\" >Perjeta ho\u1ea1t \u0111\u1ed9ng nh\u01b0 th\u1ebf n\u00e0o?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/vi\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#Dose\" >Li\u1ec1u l\u01b0\u1ee3ng<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/vi\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#Side_Effects\" >T\u00e1c d\u1ee5ng ph\u1ee5<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/vi\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#Precautions\" >C\u00e1c bi\u1ec7n ph\u00e1p ph\u00f2ng ng\u1eeba<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/vi\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#Cost\" >Tr\u1ecb gi\u00e1<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Is_Perjeta\"><\/span>Perjeta l\u00e0 g\u00ec?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Perjeta l\u00e0 m\u1ed9t lo\u1ea1i thu\u1ed1c kh\u00e1ng th\u1ec3 \u0111\u01a1n d\u00f2ng \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb m\u1ed9t s\u1ed1 lo\u1ea1i ung th\u01b0 v\u00fa. Thu\u1ed1c n\u00e0y thu\u1ed9c nh\u00f3m thu\u1ed1c \u1ee9c ch\u1ebf HER2, nh\u1eafm v\u00e0o protein HER2 \u0111\u01b0\u1ee3c t\u00ecm th\u1ea5y tr\u00ean b\u1ec1 m\u1eb7t c\u1ee7a m\u1ed9t s\u1ed1 t\u1ebf b\u00e0o ung th\u01b0 v\u00fa.<\/p>\n\n\n\n<p>Thu\u1ed1c \u0111\u00e3 \u0111\u01b0\u1ee3c&nbsp;<a href=\"https:\/\/www.fiercepharma.com\/pharma\/fda-approves-perjeta-for-neoadjuvant-breast-cancer-treatment#:~:text=Perjeta%20is%20the%20first%20FDA,)%20HER2%2Dpositive%20breast%20cancer.\">\u0111\u01b0\u1ee3c FDA Hoa K\u1ef3 ch\u1ea5p thu\u1eadn<\/a>&nbsp;N\u0103m 2012, thu\u1ed1c n\u00e0y \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng ph\u1ed1i h\u1ee3p v\u1edbi c\u00e1c thu\u1ed1c kh\u00e1c \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb ung th\u01b0 v\u00fa d\u01b0\u01a1ng t\u00ednh v\u1edbi HER2 \u0111\u00e3 di c\u0103n sang c\u00e1c b\u1ed9 ph\u1eadn kh\u00e1c c\u1ee7a c\u01a1 th\u1ec3 (ung th\u01b0 v\u00fa di c\u0103n) ho\u1eb7c \u0111\u00e3 ti\u1ebfn tri\u1ec3n t\u1ea1i ch\u1ed7 v\u00e0 kh\u00f4ng th\u1ec3 ph\u1eabu thu\u1eadt c\u1eaft b\u1ecf. FDA c\u0169ng \u0111\u00e3 ph\u00ea duy\u1ec7t thu\u1ed1c n\u00e0y \u0111\u1ec3 s\u1eed d\u1ee5ng trong \u0111i\u1ec1u tr\u1ecb t\u00e2n b\u1ed5 tr\u1ee3 (tr\u01b0\u1edbc ph\u1eabu thu\u1eadt) ung th\u01b0 v\u00fa d\u01b0\u01a1ng t\u00ednh v\u1edbi HER2 k\u1ebft h\u1ee3p v\u1edbi c\u00e1c thu\u1ed1c kh\u00e1c.<\/p>\n\n\n\n<p>S\u1ef1 ch\u1ea5p thu\u1eadn c\u1ee7a Perjeta d\u1ef1a tr\u00ean&nbsp;<a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02132949\">th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng<\/a>&nbsp;cho th\u1ea5y n\u00f3 c\u00f3 hi\u1ec7u qu\u1ea3 trong vi\u1ec7c l\u00e0m ch\u1eadm s\u1ef1 ti\u1ebfn tri\u1ec3n c\u1ee7a b\u1ec7nh v\u00e0 c\u1ea3i thi\u1ec7n kh\u1ea3 n\u0103ng s\u1ed1ng s\u00f3t n\u00f3i chung \u1edf nh\u1eefng b\u1ec7nh nh\u00e2n ung th\u01b0 v\u00fa HER2 d\u01b0\u01a1ng t\u00ednh.&nbsp;<\/p>\n\n\n\n<p>Trong m\u1ed9t nghi\u00ean c\u1ee9u, nh\u1eefng b\u1ec7nh nh\u00e2n \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb b\u1eb1ng Perjeta k\u1ebft h\u1ee3p v\u1edbi h\u00f3a tr\u1ecb li\u1ec7u v\u00e0 m\u1ed9t ch\u1ea5t \u1ee9c ch\u1ebf HER2 kh\u00e1c, Herceptin (trastuzumab), s\u1ed1ng l\u00e2u h\u01a1n so v\u1edbi nh\u1eefng b\u1ec7nh nh\u00e2n ch\u1ec9 \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb b\u1eb1ng h\u00f3a tr\u1ecb li\u1ec7u v\u00e0 Herceptin.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Is_Perjeta_Used_For\"><\/span>Perjeta \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng \u0111\u1ec3 l\u00e0m g\u00ec?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Perjeta \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng v\u1edbi c\u00e1c lo\u1ea1i thu\u1ed1c kh\u00e1c, ch\u1eb3ng h\u1ea1n nh\u01b0\u00a0<a href=\"https:\/\/ameripharmaspecialty.com\/vi\/cancer\/trastuzumab-herceptin\/\">Herceptin<\/a>\u00a0(trastuzumab) v\u00e0 Taxotere (<a href=\"https:\/\/ameripharmaspecialty.com\/vi\/discontinued\/docetaxel-taxotere\/\">docetaxel<\/a>), \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ung th\u01b0 v\u00fa di c\u0103n<\/strong>: Ung th\u01b0 v\u00fa HER2 d\u01b0\u01a1ng t\u00ednh \u0111\u00e3 di c\u0103n sang c\u00e1c b\u1ed9 ph\u1eadn kh\u00e1c c\u1ee7a c\u01a1 th\u1ec3.&nbsp;<\/li>\n\n\n\n<li><strong>Ung th\u01b0 v\u00fa giai \u0111o\u1ea1n \u0111\u1ea7u:<\/strong>&nbsp;Ung th\u01b0 ph\u1ea3i n\u1eb1m \u1edf h\u1ea1ch b\u1ea1ch huy\u1ebft ho\u1eb7c c\u00f3 k\u00edch th\u01b0\u1edbc l\u1edbn h\u01a1n 2 cm.<\/li>\n\n\n\n<li><strong>Ung th\u01b0 v\u00fa ti\u1ebfn tri\u1ec3n t\u1ea1i ch\u1ed7<\/strong>: Ung th\u01b0 v\u00fa HER2 d\u01b0\u01a1ng t\u00ednh kh\u00f4ng th\u1ec3 ph\u1eabu thu\u1eadt c\u1eaft b\u1ecf.<\/li>\n\n\n\n<li><strong>\u0110i\u1ec1u tr\u1ecb t\u00e2n b\u1ed5 tr\u1ee3<\/strong>: Ung th\u01b0 v\u00fa HER2 d\u01b0\u01a1ng t\u00ednh tr\u01b0\u1edbc khi ph\u1eabu thu\u1eadt \u0111\u1ec3 gi\u1ea3m k\u00edch th\u01b0\u1edbc kh\u1ed1i u v\u00e0 t\u0103ng c\u01a1 h\u1ed9i c\u1eaft b\u1ecf th\u00e0nh c\u00f4ng b\u1eb1ng ph\u1eabu thu\u1eadt.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_Does_Perjeta_Work\"><\/span>Perjeta ho\u1ea1t \u0111\u1ed9ng nh\u01b0 th\u1ebf n\u00e0o?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Perjeta nh\u1eafm m\u1ee5c ti\u00eau v\u00e0 ng\u0103n ch\u1eb7n protein HER2 tr\u00ean b\u1ec1 m\u1eb7t t\u1ebf b\u00e0o ung th\u01b0, gi\u00fap l\u00e0m ch\u1eadm s\u1ef1 ph\u00e1t tri\u1ec3n v\u00e0 l\u00e2y lan c\u1ee7a t\u1ebf b\u00e0o ung th\u01b0.<\/p>\n\n\n\n<p>HER2 th\u01b0\u1eddng t\u01b0\u01a1ng t\u00e1c v\u1edbi c\u00e1c protein kh\u00e1c, ch\u1eb3ng h\u1ea1n nh\u01b0 HER3, v\u00e0 k\u00edch ho\u1ea1t c\u00e1c \u0111\u01b0\u1eddng d\u1eabn truy\u1ec1n t\u00edn hi\u1ec7u b\u00ean trong t\u1ebf b\u00e0o ung th\u01b0, gi\u00fap t\u0103ng tr\u01b0\u1edfng v\u00e0 s\u1ed1ng s\u00f3t. S\u1ef1 k\u00edch ho\u1ea1t n\u00e0y c\u00f3 th\u1ec3 d\u1eabn \u0111\u1ebfn s\u1ef1 ph\u00e1t tri\u1ec3n v\u00e0 lan r\u1ed9ng kh\u00f4ng ki\u1ec3m so\u00e1t c\u1ee7a t\u1ebf b\u00e0o ung th\u01b0.<\/p>\n\n\n\n<p>Perjeta li\u00ean k\u1ebft v\u1edbi m\u1ed9t ph\u1ea7n c\u1ee5 th\u1ec3 c\u1ee7a protein HER2 \u0111\u01b0\u1ee3c g\u1ecdi l\u00e0 mi\u1ec1n ngo\u1ea1i b\u00e0o, n\u1eb1m tr\u00ean b\u1ec1 m\u1eb7t ngo\u00e0i c\u1ee7a t\u1ebf b\u00e0o ung th\u01b0. B\u1eb1ng c\u00e1ch li\u00ean k\u1ebft v\u1edbi v\u00f9ng n\u00e0y, Perjeta ng\u0103n ch\u1eb7n HER2 t\u01b0\u01a1ng t\u00e1c v\u1edbi c\u00e1c protein kh\u00e1c v\u00e0 c\u00e1c con \u0111\u01b0\u1eddng truy\u1ec1n t\u00edn hi\u1ec7u th\u00fac \u0111\u1ea9y s\u1ef1 ph\u00e1t tri\u1ec3n v\u00e0 ph\u00e2n chia c\u1ee7a t\u1ebf b\u00e0o ung th\u01b0.<\/p>\n\n\n\n<p>Perjeta c\u0169ng c\u00f3 th\u1ec3 g\u00e2y ra \u0111\u1ed9c t\u00ednh t\u1ebf b\u00e0o ph\u1ee5 thu\u1ed9c kh\u00e1ng th\u1ec3 (ADCC), \u0111\u00e2y l\u00e0 qu\u00e1 tr\u00ecnh m\u00e0 c\u00e1c t\u1ebf b\u00e0o mi\u1ec5n d\u1ecbch (t\u1ebf b\u00e0o ti\u00eau di\u1ec7t t\u1ef1 nhi\u00ean) \u0111\u01b0\u1ee3c huy \u0111\u1ed9ng \u0111\u1ec3 t\u1ea5n c\u00f4ng v\u00e0 ti\u00eau di\u1ec7t c\u00e1c t\u1ebf b\u00e0o ung th\u01b0 \u0111\u00e3 \u0111\u01b0\u1ee3c g\u1eafn nh\u00e3n Perjeta.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dose\"><\/span>Li\u1ec1u l\u01b0\u1ee3ng<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Li\u1ec1u l\u01b0\u1ee3ng ph\u1ee5 thu\u1ed9c v\u00e0o m\u1ed9t s\u1ed1 y\u1ebfu t\u1ed1, bao g\u1ed3m c\u00e2n n\u1eb7ng, ti\u1ec1n s\u1eed b\u1ec7nh, giai \u0111o\u1ea1n v\u00e0 lo\u1ea1i ung th\u01b0 v\u00fa \u0111ang \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb. Tr\u01b0\u1edbc khi b\u1eaft \u0111\u1ea7u \u0111i\u1ec1u tr\u1ecb b\u1eb1ng Perjeta, b\u00e1c s\u0129 s\u1ebd x\u00e9t nghi\u1ec7m \u0111\u1ec3 x\u00e1c \u0111\u1ecbnh b\u1ea1n c\u00f3 ung th\u01b0 d\u01b0\u01a1ng t\u00ednh v\u1edbi HER2 hay kh\u00f4ng.&nbsp;<\/p>\n\n\n\n<p>Nh\u00ecn chung, li\u1ec1u d\u00f9ng th\u00f4ng th\u01b0\u1eddng l\u00e0 840 mg truy\u1ec1n t\u0129nh m\u1ea1ch (IV) trong 60 ph\u00fat, sau \u0111\u00f3 l\u00e0 420 mg truy\u1ec1n t\u0129nh m\u1ea1ch trong 30 \u0111\u1ebfn 60 ph\u00fat c\u1ee9 sau 3 tu\u1ea7n. Perjeta \u0111\u01b0\u1ee3c d\u00f9ng ph\u1ed1i h\u1ee3p v\u1edbi Herceptin (trastuzumab) v\u00e0 c\u00e1c lo\u1ea1i h\u00f3a tr\u1ecb li\u1ec7u kh\u00e1c.<\/p>\n\n\n\n<p>Perjeta \u0111\u01b0\u1ee3c truy\u1ec1n t\u0129nh m\u1ea1ch b\u1edfi nh\u00e2n vi\u00ean y t\u1ebf t\u1ea1i b\u1ec7nh vi\u1ec7n ho\u1eb7c ph\u00f2ng kh\u00e1m. Th\u1eddi gian v\u00e0 t\u1ea7n su\u1ea5t truy\u1ec1n c\u00f3 th\u1ec3 thay \u0111\u1ed5i t\u00f9y theo ph\u00e1c \u0111\u1ed3 \u0111i\u1ec1u tr\u1ecb c\u1ee5 th\u1ec3 v\u00e0 \u0111\u00e1p \u1ee9ng c\u1ee7a b\u1ec7nh nh\u00e2n. \u0110\u1ec3 \u0111\u1ea3m b\u1ea3o s\u1eed d\u1ee5ng an to\u00e0n v\u00e0 hi\u1ec7u qu\u1ea3, \u0111i\u1ec1u quan tr\u1ecdng l\u00e0 b\u1ec7nh nh\u00e2n ph\u1ea3i tu\u00e2n th\u1ee7 li\u1ec1u l\u01b0\u1ee3ng v\u00e0 h\u01b0\u1edbng d\u1eabn s\u1eed d\u1ee5ng c\u1ee7a nh\u00e2n vi\u00ean y t\u1ebf.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Side_Effects\"><\/span>T\u00e1c d\u1ee5ng ph\u1ee5<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gi\u1ed1ng nh\u01b0 b\u1ea5t k\u1ef3 lo\u1ea1i thu\u1ed1c n\u00e0o, Perjeta (pertuzumab) c\u00f3 th\u1ec3 g\u00e2y ra t\u00e1c d\u1ee5ng ph\u1ee5, m\u1eb7c d\u00f9 kh\u00f4ng ph\u1ea3i t\u1ea5t c\u1ea3 b\u1ec7nh nh\u00e2n \u0111\u1ec1u g\u1eb7p ph\u1ea3i. M\u1ed9t s\u1ed1 t\u00e1c d\u1ee5ng ph\u1ee5 th\u01b0\u1eddng g\u1eb7p bao g\u1ed3m:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ti\u00eau ch\u1ea3y<\/li>\n\n\n\n<li>Bu\u1ed3n n\u00f4n v\u00e0 n\u00f4n<\/li>\n\n\n\n<li>M\u1ec7t m\u1ecfi<\/li>\n\n\n\n<li>R\u1ee5ng t\u00f3c<\/li>\n\n\n\n<li>Ph\u00e1t ban ho\u1eb7c k\u00edch \u1ee9ng da<\/li>\n\n\n\n<li>\u0110au b\u1ee5ng<\/li>\n\n\n\n<li>\u0110au c\u01a1<\/li>\n\n\n\n<li>\u0110au \u0111\u1ea7u<\/li>\n\n\n\n<li>Gi\u1ea3m c\u1ea3m gi\u00e1c th\u00e8m \u0103n<\/li>\n\n\n\n<li>Thi\u1ebfu m\u00e1u<\/li>\n<\/ul>\n\n\n\n<p>C\u00e1c t\u00e1c d\u1ee5ng ph\u1ee5 nghi\u00eam tr\u1ecdng h\u01a1n c\u00f3 th\u1ec3 bao g\u1ed3m:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Suy tim<\/li>\n\n\n\n<li>Ph\u1ea3n \u1ee9ng truy\u1ec1n d\u1ecbch<\/li>\n\n\n\n<li>Nhi\u1ec5m tr\u00f9ng<\/li>\n\n\n\n<li>Qu\u00e1 m\u1eabn v\u00e0 ph\u1ea3n \u1ee9ng d\u1ecb \u1ee9ng<\/li>\n<\/ul>\n\n\n\n<p>\u0110i\u1ec1u quan tr\u1ecdng l\u00e0 ph\u1ea3i th\u00f4ng b\u00e1o ngay cho nh\u00e0 cung c\u1ea5p d\u1ecbch v\u1ee5 ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe n\u1ebfu x\u1ea3y ra b\u1ea5t k\u1ef3 t\u00e1c d\u1ee5ng ph\u1ee5 n\u00e0o. Nh\u00e0 cung c\u1ea5p d\u1ecbch v\u1ee5 ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe c\u00f3 th\u1ec3 \u0111i\u1ec1u ch\u1ec9nh li\u1ec1u l\u01b0\u1ee3ng ho\u1eb7c cung c\u1ea5p ch\u0103m s\u00f3c h\u1ed7 tr\u1ee3 \u0111\u1ec3 ki\u1ec3m so\u00e1t c\u00e1c t\u00e1c d\u1ee5ng ph\u1ee5. Trong m\u1ed9t s\u1ed1 tr\u01b0\u1eddng h\u1ee3p, vi\u1ec7c \u0111i\u1ec1u tr\u1ecb b\u1eb1ng Perjeta c\u00f3 th\u1ec3 c\u1ea7n ph\u1ea3i ng\u1eebng ho\u1eb7c tr\u00ec ho\u00e3n \u0111\u1ec3 ng\u0103n ng\u1eeba c\u00e1c t\u00e1c d\u1ee5ng ph\u1ee5 kh\u00e1c.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Precautions\"><\/span>C\u00e1c bi\u1ec7n ph\u00e1p ph\u00f2ng ng\u1eeba<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Nh\u1eefng ng\u01b0\u1eddi c\u00f3 ti\u1ec1n s\u1eed b\u1ec7nh tim ho\u1eb7c nh\u1eefng ng\u01b0\u1eddi \u0111\u00e3 t\u1eebng \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb b\u1eb1ng&nbsp;<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538187\/#:~:text=Anthracyclines%20are%20drugs%20extracted%20from,effective%20anticancer%20drugs%20to%20date.\">anthracycline<\/a>&nbsp;n\u00ean \u0111\u01b0\u1ee3c theo d\u00f5i ch\u1eb7t ch\u1ebd trong qu\u00e1 tr\u00ecnh \u0111i\u1ec1u tr\u1ecb.<\/li>\n\n\n\n<li>Ph\u1ee5 n\u1eef \u0111ang mang thai ho\u1eb7c \u0111ang cho con b\u00fa kh\u00f4ng n\u00ean s\u1eed d\u1ee5ng Perjeta v\u00ec c\u00f3 nguy c\u01a1 g\u00e2y h\u1ea1i cho tr\u1ebb s\u01a1 sinh.<\/li>\n\n\n\n<li>Nh\u1eefng ng\u01b0\u1eddi b\u1ecb d\u1ecb \u1ee9ng v\u1edbi Perjeta ho\u1eb7c b\u1ea5t k\u1ef3 th\u00e0nh ph\u1ea7n n\u00e0o c\u1ee7a thu\u1ed1c kh\u00f4ng n\u00ean d\u00f9ng thu\u1ed1c n\u00e0y.<\/li>\n\n\n\n<li>Nh\u1eefng ng\u01b0\u1eddi m\u1eafc b\u1ec7nh gan ho\u1eb7c th\u1eadn v\u1eabn c\u00f3 th\u1ec3 d\u00f9ng \u0111\u01b0\u1ee3c Perjeta, nh\u01b0ng c\u00f3 th\u1ec3 c\u1ea7n theo d\u00f5i v\u00e0 \u0111i\u1ec1u ch\u1ec9nh li\u1ec1u d\u00f9ng th\u00eam.<\/li>\n\n\n\n<li>B\u1ec7nh nh\u00e2n \u0111ang d\u00f9ng Perjeta n\u00ean tr\u00e1nh ti\u00eam v\u1eafc-xin s\u1ed1ng v\u00ec ch\u01b0a bi\u1ebft c\u01a1 th\u1ec3 b\u1ea1n s\u1ebd ph\u1ea3n \u1ee9ng nh\u01b0 th\u1ebf n\u00e0o v\u1edbi v\u1eafc-xin.<\/li>\n\n\n\n<li>B\u1ec7nh nh\u00e2n n\u00ean th\u00f4ng b\u00e1o cho nh\u00e0 cung c\u1ea5p d\u1ecbch v\u1ee5 ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe v\u1ec1 t\u1ea5t c\u1ea3 c\u00e1c lo\u1ea1i thu\u1ed1c, bao g\u1ed3m thu\u1ed1c theo toa, thu\u1ed1c kh\u00f4ng k\u00ea \u0111\u01a1n v\u00e0 th\u1ef1c ph\u1ea9m ch\u1ee9c n\u0103ng th\u1ea3o d\u01b0\u1ee3c m\u00e0 h\u1ecd \u0111ang d\u00f9ng \u0111\u1ec3 \u0111\u1ea3m b\u1ea3o kh\u00f4ng c\u00f3 lo\u1ea1i thu\u1ed1c n\u00e0o ph\u1ea3n \u1ee9ng v\u1edbi Perjeta.<\/li>\n\n\n\n<li>B\u1ec7nh nh\u00e2n c\u00f3 l\u1ecbch ph\u1eabu thu\u1eadt ph\u1ea3i th\u00f4ng b\u00e1o cho nh\u00e0 cung c\u1ea5p d\u1ecbch v\u1ee5 ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe r\u1eb1ng h\u1ecd \u0111ang d\u00f9ng Perjeta.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cost\"><\/span>Tr\u1ecb gi\u00e1<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Dung d\u1ecbch ti\u00eam t\u0129nh m\u1ea1ch (IV) Perjeta (420 mg\/14 ml) c\u00f3 gi\u00e1 kho\u1ea3ng $5.534. Chi ph\u00ed n\u00e0y c\u00f3 th\u1ec3 v\u01b0\u1ee3t qu\u00e1 $99.000 cho 1 n\u0103m \u0111i\u1ec1u tr\u1ecb. N\u1ebfu kh\u00f4ng \u0111\u1ee7 kh\u1ea3 n\u0103ng chi tr\u1ea3, b\u1ea1n c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c gi\u1ea3m gi\u00e1 ho\u1eb7c \u0111\u0103ng k\u00fd c\u00e1c ch\u01b0\u01a1ng tr\u00ecnh h\u1ed7 tr\u1ee3 t\u00e0i ch\u00ednh \u0111\u1ec3 b\u00f9 \u0111\u1eafp chi ph\u00ed.<\/p>","protected":false},"excerpt":{"rendered":"<p>HER2 (th\u1ee5 th\u1ec3 y\u1ebfu t\u1ed1 t\u0103ng tr\u01b0\u1edfng bi\u1ec3u b\u00ec ng\u01b0\u1eddi 2) l\u00e0 m\u1ed9t lo\u1ea1i protein \u0111\u01b0\u1ee3c t\u00ecm th\u1ea5y tr\u00ean b\u1ec1 m\u1eb7t c\u1ee7a m\u1ed9t s\u1ed1 t\u1ebf b\u00e0o (v\u00ed d\u1ee5, t\u1ebf b\u00e0o v\u00fa) c\u00f3 vai tr\u00f2 trong qu\u00e1 tr\u00ecnh t\u0103ng tr\u01b0\u1edfng v\u00e0 ph\u00e2n chia t\u1ebf b\u00e0o.<br \/>\n\u0110\u00f4i khi, c\u00e1c t\u1ebf b\u00e0o ung th\u01b0 v\u00fa c\u00f3 th\u1ec3 c\u00f3 qu\u00e1 nhi\u1ec1u b\u1ea3n sao c\u1ee7a gen HER2, d\u1eabn \u0111\u1ebfn qu\u00e1 nhi\u1ec1u protein HER2 tr\u00ean b\u1ec1 m\u1eb7t t\u1ebf b\u00e0o.<\/p>","protected":false},"author":26,"featured_media":24705,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[64],"tags":[],"class_list":["post-24704","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-discontinued"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer<\/title>\n<meta name=\"description\" content=\"Find out how Perjeta treats HER2-positive breast cancer. Topics include how the drug works, dosage, side effects, precautions, and cost.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/vi\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"vi_VN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"Find out how Perjeta treats HER2-positive breast cancer. Topics include how the drug works, dosage, side effects, precautions, and cost.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/vi\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-07T09:02:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T21:39:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Robert Hakim, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Robert Hakim, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 ph\u00fat\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/\"},\"author\":{\"name\":\"Dr. Robert Hakim, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/person\\\/234280933b6e0dcaf47c0c1f40a59759\"},\"headline\":\"Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer\",\"datePublished\":\"2023-11-07T09:02:00+00:00\",\"dateModified\":\"2026-03-20T21:39:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/\"},\"wordCount\":979,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg\",\"articleSection\":[\"Discontinued\"],\"inLanguage\":\"vi\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/\",\"name\":\"Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg\",\"datePublished\":\"2023-11-07T09:02:00+00:00\",\"dateModified\":\"2026-03-20T21:39:21+00:00\",\"description\":\"Find out how Perjeta treats HER2-positive breast cancer. Topics include how the drug works, dosage, side effects, precautions, and cost.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"vi\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"vi\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Medication for HER2-positive breast cancer treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vi\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vi\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/person\\\/234280933b6e0dcaf47c0c1f40a59759\",\"name\":\"Dr. Robert Hakim, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vi\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g\",\"caption\":\"Dr. Robert Hakim, PharmD\"},\"description\":\"Dr. Robert Chad Hakim, PharmD, was born and raised in Northridge, CA. He received his pharmacy degree from the University of Wisconsin-Madison School of Pharmacy. The most rewarding part of his job is taking initiative to advance clinical programs that maximize impact on patient care. He has a board certification in critical care (BCCCP), and his areas of expertise are critical care, drug information, general medicine, and cardiology. In his free time, he enjoys traveling.\u00a0\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/author\\\/robert-hakim\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Perjeta (Pertuzumab): M\u1ed9t lo\u1ea1i thu\u1ed1c \u0111\u1ea7y h\u1ee9a h\u1eb9n cho b\u1ec7nh ung th\u01b0 v\u00fa d\u01b0\u01a1ng t\u00ednh v\u1edbi HER2","description":"T\u00ecm hi\u1ec3u c\u00e1ch thu\u1ed1c Perjeta \u0111i\u1ec1u tr\u1ecb ung th\u01b0 v\u00fa d\u01b0\u01a1ng t\u00ednh v\u1edbi HER2. C\u00e1c ch\u1ee7 \u0111\u1ec1 bao g\u1ed3m c\u01a1 ch\u1ebf ho\u1ea1t \u0111\u1ed9ng, li\u1ec1u d\u00f9ng, t\u00e1c d\u1ee5ng ph\u1ee5, bi\u1ec7n ph\u00e1p ph\u00f2ng ng\u1eeba v\u00e0 chi ph\u00ed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/vi\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/","og_locale":"vi_VN","og_type":"article","og_title":"Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer","og_description":"Find out how Perjeta treats HER2-positive breast cancer. Topics include how the drug works, dosage, side effects, precautions, and cost.","og_url":"https:\/\/ameripharmaspecialty.com\/vi\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2023-11-07T09:02:00+00:00","article_modified_time":"2026-03-20T21:39:21+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg","type":"image\/jpeg"}],"author":"Dr. Robert Hakim, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Robert Hakim, PharmD","Est. reading time":"5 ph\u00fat"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/"},"author":{"name":"Dr. Robert Hakim, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/person\/234280933b6e0dcaf47c0c1f40a59759"},"headline":"Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer","datePublished":"2023-11-07T09:02:00+00:00","dateModified":"2026-03-20T21:39:21+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/"},"wordCount":979,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg","articleSection":["Discontinued"],"inLanguage":"vi"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/","url":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/","name":"Perjeta (Pertuzumab): M\u1ed9t lo\u1ea1i thu\u1ed1c \u0111\u1ea7y h\u1ee9a h\u1eb9n cho b\u1ec7nh ung th\u01b0 v\u00fa d\u01b0\u01a1ng t\u00ednh v\u1edbi HER2","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg","datePublished":"2023-11-07T09:02:00+00:00","dateModified":"2026-03-20T21:39:21+00:00","description":"T\u00ecm hi\u1ec3u c\u00e1ch thu\u1ed1c Perjeta \u0111i\u1ec1u tr\u1ecb ung th\u01b0 v\u00fa d\u01b0\u01a1ng t\u00ednh v\u1edbi HER2. C\u00e1c ch\u1ee7 \u0111\u1ec1 bao g\u1ed3m c\u01a1 ch\u1ebf ho\u1ea1t \u0111\u1ed9ng, li\u1ec1u d\u00f9ng, t\u00e1c d\u1ee5ng ph\u1ee5, bi\u1ec7n ph\u00e1p ph\u00f2ng ng\u1eeba v\u00e0 chi ph\u00ed.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#breadcrumb"},"inLanguage":"vi","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"vi","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg","width":1280,"height":853,"caption":"Medication for HER2-positive breast cancer treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/"},{"@type":"ListItem","position":2,"name":"Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/es\/#website","url":"https:\/\/ameripharmaspecialty.com\/es\/","name":"Ch\u0103m s\u00f3c \u0111\u1eb7c bi\u1ec7t AmeriPharma\u00ae","description":"Ch\u0103m s\u00f3c \u0111\u1eb7c bi\u1ec7t c\u1ee7a AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vi"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/es\/#organization","name":"Ch\u0103m s\u00f3c \u0111\u1eb7c bi\u1ec7t Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"vi","@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/person\/234280933b6e0dcaf47c0c1f40a59759","name":"Ti\u1ebfn s\u0129 Robert Hakim, Ti\u1ebfn s\u0129 D\u01b0\u1ee3c","image":{"@type":"ImageObject","inLanguage":"vi","@id":"https:\/\/secure.gravatar.com\/avatar\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g","caption":"Dr. Robert Hakim, PharmD"},"description":"Ti\u1ebfn s\u0129 Robert Chad Hakim, PharmD, sinh ra v\u00e0 l\u1edbn l\u00ean t\u1ea1i Northridge, CA. \u00d4ng nh\u1eadn b\u1eb1ng d\u01b0\u1ee3c s\u0129 t\u1eeb Tr\u01b0\u1eddng D\u01b0\u1ee3c thu\u1ed9c \u0110\u1ea1i h\u1ecdc Wisconsin-Madison. Ph\u1ea7n b\u1ed5 \u00edch nh\u1ea5t trong c\u00f4ng vi\u1ec7c c\u1ee7a \u00f4ng l\u00e0 ch\u1ee7 \u0111\u1ed9ng th\u00fac \u0111\u1ea9y c\u00e1c ch\u01b0\u01a1ng tr\u00ecnh l\u00e2m s\u00e0ng nh\u1eb1m t\u1ed1i \u0111a h\u00f3a t\u00e1c \u0111\u1ed9ng \u0111\u1ebfn vi\u1ec7c ch\u0103m s\u00f3c b\u1ec7nh nh\u00e2n. \u00d4ng c\u00f3 ch\u1ee9ng ch\u1ec9 h\u00e0nh ngh\u1ec1 ch\u0103m s\u00f3c \u0111\u1eb7c bi\u1ec7t (BCCCP) v\u00e0 c\u00e1c l\u0129nh v\u1ef1c chuy\u00ean m\u00f4n c\u1ee7a \u00f4ng l\u00e0 ch\u0103m s\u00f3c \u0111\u1eb7c bi\u1ec7t, th\u00f4ng tin v\u1ec1 thu\u1ed1c, y h\u1ecdc t\u1ed5ng qu\u00e1t v\u00e0 tim m\u1ea1ch. Trong th\u1eddi gian r\u1ea3nh r\u1ed7i, \u00f4ng th\u00edch \u0111i du l\u1ecbch.\u00a0","url":"https:\/\/ameripharmaspecialty.com\/vi\/author\/robert-hakim\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Robert Hakim, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/vi\/author\/robert-hakim\/"},"uagb_comment_info":0,"uagb_excerpt":"HER2 (human epidermal growth factor receptor 2) is a protein found on the surface of some cells (e.g., breast cells) that plays a role in cell growth and division. Sometimes, breast cancer cells can have too many copies of the HER2 gene, leading to too much HER2 protein on the surface of the cells.","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Robert Hakim, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/vi\/author\/robert-hakim\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/vi\/category\/discontinued\/\" rel=\"category tag\">Discontinued<\/a>","rttpg_excerpt":"HER2 (human epidermal growth factor receptor 2) is a protein found on the surface of some cells (e.g., breast cells) that plays a role in cell growth and division. Sometimes, breast cancer cells can have too many copies of the HER2 gene, leading to too much HER2 protein on the surface of the cells.","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/vi\/wp-json\/wp\/v2\/posts\/24704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/vi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/vi\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/vi\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/vi\/wp-json\/wp\/v2\/comments?post=24704"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/vi\/wp-json\/wp\/v2\/posts\/24704\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/vi\/wp-json\/wp\/v2\/media\/24705"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/vi\/wp-json\/wp\/v2\/media?parent=24704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/vi\/wp-json\/wp\/v2\/categories?post=24704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/vi\/wp-json\/wp\/v2\/tags?post=24704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}